IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that Pierre Labb, IMVs Chief Financial Officer will present at the Cowen and Company 39th Annual Health Care Conference, which will be held March 11-13, 2019 in Boston, MA.
IMVs presentation details include:
- Date: Wednesday, March 13, 2019
- Time: 9:20 “ 9:50 a.m. ET
- Location: Salon C, 4th Floor at The Marriott Copley Hotel, Boston, MA
There will be a live webcast of IMVs presentation accessible thru the IMV website at: http://wsw.com/webcast/cowen52/imv/ and the presentation will then be archived for 90 days afterwards. A copy of the presentation will also be available in the Events & Presentations section of IMVs website: www.imv-inc.com.
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Companys proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMVs lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at www.imv-inc.com.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
Marc Jasmin, IMV Senior Director,
Investor Relations and Communications
O: (902) 492-1819 ext : 1042
(514) 617-9481 E: [email protected]
Andrea Cohen, Sam Brown Inc.
209-7163 E: [email protected]